Clinical Trials Logo

Filter by:
NCT ID: NCT04803409 Active, not recruiting - Covid19 Clinical Trials

UNITE Study (UCSD-SW) for COVID-19

UNITE
Start date: March 22, 2021
Phase: N/A
Study type: Interventional

The research objective of the UNITE Study is to assess the potential efficacy of ultrasound application to the spleen using a small wearable ultrasound system in the treatment of coronavirus disease 2019 (COVID-19) in a pilot study. Specific Aims: Determine the efficacy of splenic ultrasound in affecting markers of systemic inflammation in COVID-19 infection. Evaluate the potential efficacy of splenic ultrasound in affecting clinical outcomes in COVID-19 infection. Condition or disease: Covid19: Cytokine Storm Inflammation Device: Splenic Ultrasound Phase: Not Applicable

NCT ID: NCT04803214 Active, not recruiting - Clinical trials for Chronic Low-back Pain

ReActiv8 Stimulation Therapy vs Optimal Medical Management: A Randomized Evaluation

RESTORE
Start date: July 14, 2021
Phase: N/A
Study type: Interventional

This study is a prospective, randomized study comparing ReActiv8 Therapy to Optimal Medical Management (OMM).

NCT ID: NCT04803149 Active, not recruiting - Clinical trials for Chronic Low-back Pain

Cooled RFA vs Conventional RFA to Manage Chronic Facetogenic Low Back Pain

Lumbar CvS
Start date: February 23, 2021
Phase: N/A
Study type: Interventional

This study is being conducted to assess the relative effectiveness of radiofrequency neurotomy in subjects with chronic axial low back pain originating in the lumbar facet joints using the COOLIEF* Cooled Radiofrequency Probe as compared to the same procedure conducted using a Standard Radiofrequency Probe.

NCT ID: NCT04802733 Active, not recruiting - Clinical trials for Advanced Parkinson's Disease

Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson's Disease

Start date: May 3, 2021
Phase: Phase 1
Study type: Interventional

This clinical trial is designed to test whether surgically injecting nerve cells that make dopamine into the brain of Parkinson's disease patients is safe, and to monitor for potential side effects.

NCT ID: NCT04801758 Active, not recruiting - HIV Infection Clinical Trials

Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 704/HPTN 085 AMP Study

Start date: August 22, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to learn whether having the AMP Study antibody (called VRC01) in a person's body might help their immune system control HIV better, even without HIV medication called antiretroviral therapy or ART, if they get HIV. This study will evaluate the viral and immune system responses in an Analytical Treatment Interruption (ATI), in participants who received VRC01 or placebo and got HIV while enrolled in HVTN 704/HPTN 085 (NCT02716675). Participants in this study will stop taking their HIV medication. They will stay off HIV medication unless and until the HIV levels in their blood show that their immune system is unable to control the HIV or they meet other ART re-start criteria as noted in section "Detailed Description". While they are not taking HIV medication, their HIV levels will be tested frequently, and their health will be monitored closely. This is called an analytical treatment interruption, or an ATI. An ATI is an experimental procedure that is only used in carefully monitored research.

NCT ID: NCT04801420 Active, not recruiting - Lyme Borreliosis Clinical Trials

Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study Population

Start date: March 8, 2021
Phase: Phase 2
Study type: Interventional

VLA15-221 is a Phase 2 study, which will be conducted in two parts: Main Study Phase (Part A) and Booster Phase (Part B). The study will compare the safety and immunogenicity of two different primary immunization schedules applying three (Month 0-2-6) or two (Month 0- 6) vaccinations. Within the study, 600 healthy subjects aged 5-65 years will be included. Subjects with a history of Lyme borreliosis (previous infection with Borrelia) as well as Borrelia naïve subjects will be enrolled. Study duration per subject will be a maximum of 56 months per subject.

NCT ID: NCT04800874 Active, not recruiting - LGMD2I Clinical Trials

Study of BBP-418 in Patients With LGMD2I

Start date: February 18, 2021
Phase: Phase 2
Study type: Interventional

BBP-418 is being developed for the treatment of patients with Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I). This is an open label study to determine the safety and tolerability of ascending dose levels of BBP-418 in the treatment of ambulatory and non-ambulatory patients with LGMD2I for which no approved therapy currently exists.

NCT ID: NCT04800822 Active, not recruiting - Solid Tumor Clinical Trials

PF-07284892 in Participants With Advanced Solid Tumors

Start date: March 17, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this first-in-patient, open label study is to determine the maximum tolerated dose and/or recommended dose for further study of PF-07284892 as a single agent and in combination with lorlatinib, encorafenib and cetuximab, or binimetinib and evaluate the pharmacokinetics, safety, and preliminary clinical activity of single agent and each combination therapy.

NCT ID: NCT04800471 Active, not recruiting - Diabetes Mellitus Clinical Trials

Improving Glycemic Control in DM2 Patients in the Ambulatory Setting

Start date: August 16, 2021
Phase: N/A
Study type: Interventional

More than 10.5% of the US population has diabetes mellitus. The objective of this pilot study is to evaluate whether smart insulin pens combined with CGM devices can improve glucose control in patients with type 2 diabetes (T2D)

NCT ID: NCT04800107 Active, not recruiting - Clinical trials for Tinnitus, Subjective

Effect of Highly Bioavailable Curcumin on Subjective Tinnitus

Start date: January 6, 2021
Phase: N/A
Study type: Interventional

This study will assess the effectiveness of highly bioavailable curcumin in suppressing subjective tinnitus based on pre- and post-treatment evaluations using the validated Tinnitus Functional Index (TFI) and Tinnitus Handicap Inventory (THI) surveys.